Matthew Scott Harris - 25 Jan 2025 Form 4 Insider Report for Altimmune, Inc. (ALT)

Reporting relationship: Chief Medical Officer
Issuer ticker: ALT
Reported as of: 25 Jan 2025
Net transaction value: -$34,858
SEC form: 4
Accepted by SEC: 28 Jan 2025, 21:05:20 UTC
Prior SEC filing: 01 Aug 2024
Next SEC filing: 03 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Greg Weaver, as Attorney-in-Fact

Key filing fact

Matthew Scott Harris filed Form 4 for Altimmune, Inc. (ALT) on 28 Jan 2025.

Key facts

This page summarizes Matthew Scott Harris's Form 4 filing for Altimmune, Inc. (ALT).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 28 Jan 2025, 21:05.

Change

Previous filing in this sequence was filed on 01 Aug 2024.
Current net transaction value: -$34,858.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALT transaction

Common Stock, par value $0.0001

Options Exercise

Transaction value: $0
Shares: +14,600
Change %: +26%
Price: $0.000000
Shares after: 69,719
Date: 25 Jan 2025
Ownership: Direct
Footnotes: F1

ALT transaction

Common Stock, par value $0.0001

Tax liability

Transaction value: $34,858
Shares: -4,994
Change %: -7.2%
Price: $6.98
Shares after: 64,725
Date: 25 Jan 2025
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALT transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: +14,600
Change %: +50%
Price: $0.000000
Shares after: 43,800
Date: 25 Jan 2025
Ownership: Direct
Underlying class: Common Stock, par value $0.0001
Underlying amount: 14,600
Exercise price
Footnotes: F1, F3

ALT transaction Derivative

Stock Options (option to buy)

Award

Transaction value: $0
Shares: +183,600
Change %
Price: $0.000000
Shares after: 183,600
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock, par value $0.0001
Underlying amount: 183,600
Exercise price: $7.00
Footnotes: F4

ALT transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +63,400
Change %
Price: $0.000000
Shares after: 63,400
Date: 27 Jan 2025
Ownership: Direct
Underlying class: Common Stock, par value $0.0001
Underlying amount: 63,400
Exercise price
Footnotes: F1, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.

Footnote F2

Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.

Footnote F3

The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

Footnote F4

Twenty-five percent of the shares underlying the option become vested and released on January 27, 2026 and the remaining 75% of the shares underlying the option become vested and released in substantially equal monthly installments over the 36 months following January 27, 2026, subject to the reporting person's continued service through the applicable vesting date.

Footnote F5

The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

SEC remarks

Exhibit 24 - Power of Attorney.